ElizabethB.SmithMD

PubMed

• HIV Cell Fusion Assay: Phenotypic Screening Tool for the Identification of HIV Entry Inhibitors via CXCR4.
  Smith, E. B.,Ogert, R. A.,Pechter, D.,Villafania, A.,Abbondanzo, S. J.,Lin, K.,Rivera-Gines, A.,Rebsch-Mastykarz, C.,Monsma, F. J.> ;J Biomol Screen. 2013 Aug 29
• SCH 1473759, a novel Aurora inhibitor, demonstrates enhanced anti-tumor activity in combination with taxanes and KSP inhibitors.
  Basso, A. D.,Liu, M.,Gray, K.,Tevar, S.,Lee, S.,Liang, L.,Ponery, A.,Smith, E. B.,Monsma, F. J.,Yu, T.,Zhang, Y.,Kerekes, A. D.,Esposite, S.,Xiao, Y.,Tagat, J. R.,Hick...> ;Cancer Chemother Pharmacol. 2011 Oct
• In-vivo characterization of optical properties of pigmented skin lesions including melanoma using oblique incidence diffuse reflectance spectrometry.
  Garcia-Uribe, A., Smith, E.B., Zou, J., Duvic, M., Prieto, V., Wang, L.V.> ;J Biomed Opt. 2011 Feb
• Aurora Kinase Inhibitors Based on the Imidazo[1,2-a]pyrazine Core: Fluorine and Deuterium Incorporation Improve Oral Absorption and Exposure.
  Kerekes, A.D., Esposite, S.J., Doll, R.J., Tagat, J.R., Yu, T., Xiao, Y., Zhang, Y., Prelusky, D.B., Tevar, S., Gray, K., Terracina, G.A., Lee, S., Jones, J., Liu, M.,...> ;J Med Chem. 2011 Jan 13
• Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitors.
  Meng, Z., Kulkarni, B. A., Kerekes, A. D., Mandal, A. K., Esposite, S. J., Belanger, D. B., Reddy, P. A., Basso, A. D., Tevar, S., Gray, K., Jones, J., Smith, E. B., D...> ;Bioorg Med Chem Lett. 2011 Jan 1
• Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
  Belanger, D. B., Williams, M. J., Curran, P. J., Mandal, A. K., Meng, Z., Rainka, M. P., Yu, T., Shih, N. Y., Siddiqui, M. A., Liu, M., Tevar, S., Lee, S., Liang, L., ...> ;Bioorg Med Chem Lett. 2010 Nov 15
• Join now to see all